glp-1 agonist list Market Overview: Agonists and the Obesity Market | Blog List of approved and pending

We strive to preserve coverage for other lifesaving procedures for our members

Probst L, Monnerat S, Vogt DR, Lengsfeld S, Burkard T, Meienberg A, et al

Side Effect Profile Gastrointestinal (GI) side effects, including nausea, vomiting, diarrhea, and constipation, are the most frequently reported issues with GLP-1 medications and are one of the top reasons people discontinue treatment

Therapeutic response is dose- and time-dependent: The maximal improvements in aminotransferases and liver fat content typically occur around 28 to 30 weeks after initiating therapy, indicating that sustained treatment is necessary to achieve optimal benefit

In addition, there is the potential for an increased incidence of hypersensitivity reactions such as injection-site reactions

Studies suggest that: Patients with insulin resistance may respond better to GLP-1/GIP dual agonists (eg, tirzepatide)